Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Opus Genetics, Inc. is a biotech company developing gene therapies for inherited retinal diseases (IRDs) and ophthalmic disorders. Its pipeline includes AAV-based gene treatments targeting conditions like Leber congenital amaurosis, retinitis pigmentosa, and Best disease. The company also commercializes the FDA-approved RYZUMVI eye drop for presbyopia and low-light vision issues, focusing on innovative, one-time treatments for vision loss and eye health.
This description was generated via AI from an annual report. Updated about 1 year ago.